{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:56:53Z","timestamp":1792821413352,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11688-7","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:14:34Z","timestamp":1760451274000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Research mapping and comparative assessment of drug treatment regimens for brucellosis: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Abbas","family":"Pele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Masudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahim Nejad","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"2","key":"11688_CR1","first-page":"83","volume":"2","author":"MR Hassanjani Roshan","year":"2001","unstructured":"Hassanjani Roshan MR. Comparison of the efficacy of two months of treatment with Co-trimoxasol\u2009+\u2009Rifampine versus Doxycycline\u2009+\u2009Rifampine in brucellosis. Koomesh J. 2001;2(2):83\u20137.","journal-title":"Koomesh J"},{"key":"11688_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2165\/00003495-199753020-00005","volume":"53","author":"J Solera","year":"1997","unstructured":"Solera J, Martinez-Alfaro E, Espinosa A. Recognition and optimum treatment of brucellosis. Drugs. 1997;53:245\u201356.","journal-title":"Drugs"},{"issue":"6","key":"11688_CR3","first-page":"349","volume":"21","author":"M Golshani","year":"2017","unstructured":"Golshani M, Buozari S. A review of brucellosis in iran: epidemiology, risk factors, diagnosis, control, and prevention. Iran Biomed J. 2017;21(6):349.","journal-title":"Iran Biomed J"},{"issue":"12","key":"11688_CR4","first-page":"2791","volume":"51","author":"M Zeinali","year":"2022","unstructured":"Zeinali M, Doosti S, Amiri B, Gouya MM, Godwin GN. Trends in the epidemiology of brucellosis cases in Iran during the last decade. Iran J Public Health. 2022;51(12):2791.","journal-title":"Iran J Public Health"},{"issue":"12","key":"11688_CR5","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1371\/journal.pmed.0040317","volume":"4","author":"J Ariza","year":"2007","unstructured":"Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, Memish ZA, Roushan MRH, Rubinstein E, Sipsas NV, et al. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. PLoS Med. 2007;4(12):e317.","journal-title":"PLoS Med"},{"issue":"5","key":"11688_CR6","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s15010-021-01586-w","volume":"49","author":"M Bosilkovski","year":"2021","unstructured":"Bosilkovski M, Keramat F, Arapovi\u0107 J. The current therapeutical strategies in human brucellosis. Infection. 2021;49(5):823\u201332.","journal-title":"Infection"},{"issue":"2","key":"11688_CR7","first-page":"636","volume":"4","author":"SM Alavi","year":"2013","unstructured":"Alavi SM, Alavi L. Treatment of brucellosis: a systematic review of studies in recent Twenty years. Casp J Intern Med. 2013;4(2):636\u201341.","journal-title":"Casp J Intern Med"},{"key":"11688_CR8","first-page":"636","volume":"36 9","author":"A L\u00f3pez-Merino","year":"2004","unstructured":"L\u00f3pez-Merino A, Contreras-Rodr\u00edguez A, Migranas-Ortiz R, Orrantia-Grad\u00edn R, Hern\u00e1ndez-Oliva G, Guti\u00e9rrez-Rubio ATY, Carde\u00f1osa O. Susceptibility of Mexican Brucella isolates to moxifloxacin, Ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis. 2004;36 9:636\u20138.","journal-title":"Scand J Infect Dis"},{"key":"11688_CR9","unstructured":"Shirzadi M, Zeinali M, F R. Guideline for the diagnosis and management of brucellosis, vol. 1: Andishmand 1392:69\u201371."},{"issue":"2","key":"11688_CR10","doi-asserted-by":"publisher","first-page":"e0191993","DOI":"10.1371\/journal.pone.0191993","volume":"13","author":"F Meng","year":"2018","unstructured":"Meng F, Pan X, Tong W. Rifampicin versus streptomycin for brucellosis treatment in humans: A meta-analysis of randomized controlled trials. PLoS ONE. 2018;13(2):e0191993.","journal-title":"PLoS ONE"},{"issue":"7646","key":"11688_CR11","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1136\/bmj.39497.500903.25","volume":"336","author":"K Skalsky","year":"2008","unstructured":"Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. BMJ. 2008;336(7646):701\u20134.","journal-title":"BMJ"},{"issue":"2","key":"11688_CR12","doi-asserted-by":"publisher","first-page":"e32090","DOI":"10.1371\/journal.pone.0032090","volume":"7","author":"J del Sol\u00eds Garc\u00eda","year":"2012","unstructured":"del Sol\u00eds Garc\u00eda J, Solera J. Systematic review and meta-analysis of randomized clinical trials in the treatment of human brucellosis. PLoS ONE. 2012;7(2):e32090.","journal-title":"PLoS ONE"},{"key":"11688_CR13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11739-016-1583-7","volume":"12","author":"B Rouse","year":"2017","unstructured":"Rouse B, Chaimani A, Li T. Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2017;12:103\u201311.","journal-title":"Intern Emerg Med"},{"key":"11688_CR14","unstructured":"Doosti-Irani ACZ. An introduction to network Meta-Analysis. Sci J Hamdan Univ Med Sci. 2021:18\u201320."},{"key":"11688_CR15","unstructured":"SM A. Comparison of two chemotherapy regimen: doxycycline-rifampicin and doxycycline cotrimoxazol in the brucellosis patients Ahvaz, Iran, 2004\u20132006. 2007."},{"issue":"3","key":"11688_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jac\/23.3.433","volume":"23","author":"G Acocella","year":"1989","unstructured":"Acocella G, Bertrand A, Beytout J, Durrande JB, Rodriguez J-AG, Kosmidis J, Micoud M, Rey M, Zapata MR, Roux J. Comparison of three different regimens in the treatment of acute brucellosis: a multicenter multinational study. J Antimicrob Chemother. 1989;23(3):433\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"11688_CR17","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s100960050344","volume":"18","author":"C Agalar","year":"1999","unstructured":"Agalar C, Usubutun S, Turkyilmaz R. Ciprofloxacin and rifampicin versus Doxycycline and rifampicin in the treatment of brucellosis. Eur J Clin Microbiol Infect Dis. 1999;18:535\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"11688_CR18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1128\/AAC.37.9.1831","volume":"37","author":"M Akova","year":"1993","unstructured":"Akova M, Uzun O, Akalin HE, Hayran M, Unal S, G\u00fcr D. Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. Antimicrob Agents Chemother. 1993;37(9):1831\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"85","key":"11688_CR19","first-page":"60","volume":"25","author":"A Alikhani","year":"2007","unstructured":"Alikhani A, Heidarzadeh A. A new therapeutic management in acute uncomplicated brucellosis: comparison between three Month-Ofloxacin and Doxycycline-based regimens. J Isfahan Med Sch. 2007;25(85):60\u201355.","journal-title":"J Isfahan Med Sch"},{"issue":"1","key":"11688_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-6-72","volume":"6","author":"E Alp","year":"2006","unstructured":"Alp E, Koc RK, Durak AC, Yildiz O, Aygen B, Sumerkan B, Doganay M. Doxycycline plus streptomycin versus Ciprofloxacin plus rifampicin in spinal brucellosis [ISRCTN31053647]. BMC Infect Dis. 2006;6(1):1\u201310.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"11688_CR21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/infdis\/152.6.1358","volume":"152","author":"J Ariza","year":"1985","unstructured":"Ariza J, Gudiol F, Pallares R, Rufi G, Fernandez-Viladrich P. Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis. 1985;152(6):1358\u20139.","journal-title":"J Infect Dis"},{"issue":"1","key":"11688_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-117-1-25","volume":"117","author":"J Ariza","year":"1992","unstructured":"Ariza J, Gudiol F, Pallares R, Viladrich PF, Rufi G, Corredoira J, Miravitlles MR. Treatment of human brucellosis with Doxycycline plus Rifampin or Doxycycline plus streptomycin: a randomized, double-blind study. Ann Intern Med. 1992;117(1):25\u201330.","journal-title":"Ann Intern Med"},{"issue":"5","key":"11688_CR23","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1179\/joc.2003.15.5.466","volume":"15","author":"Y Bayindir","year":"2003","unstructured":"Bayindir Y, Sonmez E, Aladag A, Buyukberber N. Comparison of five antimicrobial regimens for the treatment of Brucellar spondylitis: a prospective, randomized study. J Chemother. 2003;15(5):466\u201371.","journal-title":"J Chemother"},{"issue":"2","key":"11688_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000238662","volume":"35","author":"C Castillo","year":"1989","unstructured":"Castillo C, Marquez H, Iglesias R, Franquelo C, Diaz R, Alonso A. Comparative trial of Doxycycline plus streptomycin versus Doxycycline plus Rifampin for the therapy of human brucellosis. Chemotherapy. 1989;35(2):146\u201352.","journal-title":"Chemotherapy"},{"issue":"12","key":"11688_CR25","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1128\/AAC.38.12.2798","volume":"38","author":"J Colmenero","year":"1994","unstructured":"Colmenero J, Fernandez-Gallardo L, Agundez J, Sedeno J, Benitez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. Antimicrob Agents Chemother. 1994;38(12):2798\u2013802.","journal-title":"Antimicrob Agents Chemother"},{"key":"11688_CR26","unstructured":"Didgar F, Sarmadian H, Zarrinfar N, Rafiee M, Choghae M. Comparison between efficacy of Ciprofioxacin-Doxycycline and Rifampin-Doxycycline regimens in treatment of brucellosis. J Zanjan Univ Med Sci. 2012;20(80):12\u20139."},{"issue":"4","key":"11688_CR27","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1258\/004947505774938765","volume":"35","author":"Y Ersoy","year":"2005","unstructured":"Ersoy Y, Sonmez E, Tevfik MR, But AD. Comparison of three different combination therapies in the treatment of human brucellosis. Trop Doct. 2005;35(4):210\u20132.","journal-title":"Trop Doct"},{"key":"11688_CR28","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bjid.2016.02.004","volume":"20","author":"A Hasanain","year":"2016","unstructured":"Hasanain A, Mahdy R, Mohamed A, Ali M. A randomized, comparative study of dual therapy (doxycycline\u2013rifampin) versus triple therapy (doxycycline\u2013rifampin\u2013levofloxacin) for treating acute\/subacute brucellosis. Braz J Infect Dis. 2016;20:250\u20134.","journal-title":"Braz J Infect Dis"},{"issue":"4","key":"11688_CR29","first-page":"e247","volume":"16","author":"SH Hashemi","year":"2012","unstructured":"Hashemi SH, Gachkar L, Keramat F, Mamani M, Hajilooi M, Janbakhsh A, Majzoobi MM, Mahjub H. Comparison of doxycycline\u2013streptomycin, doxycycline\u2013rifampin, and ofloxacin\u2013rifampin in the treatment of brucellosis: a randomized clinical trial. IJID One Health. 2012;16(4):e247\u201351.","journal-title":"IJID One Health"},{"key":"11688_CR30","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0399-077X(96)80077-1","volume":"26","author":"T Kalo","year":"1996","unstructured":"Kalo T, Novi S, Nushi A, Dedja S. Ciprofloxacin plus Doxycycline versus rifampicin plus Doxycycline in the treatment of acute brucellosis. Med Mal Infect. 1996;26:587\u20139.","journal-title":"Med Mal Infect"},{"issue":"1","key":"11688_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2334-4-18","volume":"4","author":"O Karabay","year":"2004","unstructured":"Karabay O, Sencan I, Kayas D, \u015eahin I. Ofloxacin plus rifampicin versus Doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]. BMC Infect Dis. 2004;4(1):1\u20136.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"11688_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1258\/td.2009.090030","volume":"39","author":"F Keramat","year":"2009","unstructured":"Keramat F, Ranjbar M, Mamani M, Hashemi SH, Zeraati F. A comparative trial of three therapeutic regimens: ciprofloxacin-rifampin, ciprofloxacin-doxycycline and doxycycline-rifampin in the treatment of brucellosis. Trop Doct. 2009;39(4):207\u201310.","journal-title":"Trop Doct"},{"issue":"6","key":"11688_CR33","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/jac\/26.6.841","volume":"26","author":"R Lang","year":"1990","unstructured":"Lang R, Raoul R, Sacks T, Shapiro M. Failure of prolonged treatment with Dprofloxadn in acute infections Dueto Brucella melitensis. J Antimicrob Chemother. 1990;26(6):841\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"11688_CR34","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/clinids\/14.2.506","volume":"14","author":"R Lang","year":"1992","unstructured":"Lang R, Dagan R, Potasman I, Einhorn M, Raz R. Failure of ceftriaxone in the treatment of acute brucellosis. Clin Infect Dis. 1992;14(2):506\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"11688_CR35","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijantimicag.2017.08.009","volume":"51","author":"MM Majzoobi","year":"2018","unstructured":"Majzoobi MM, Hashemi SH, Mamani M, Keramat F, Poorolajal J, Basir HRG. Effect of hydroxychloroquine on treatment and recurrence of acute brucellosis: a single-blind, randomized clinical trial. Int J Antimicrob Agents. 2018;51(3):365\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"11688_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1258\/td.2011.110284","volume":"42","author":"B Mile","year":"2012","unstructured":"Mile B, Valerija K, Krsto G, Ivan V, Ilir D, Nikola L. Doxycycline-rifampin versus doxycycline-rifampin-gentamicin in treatment of human brucellosis. Trop Doct. 2012;42(1):13\u20137.","journal-title":"Trop Doct"},{"issue":"5","key":"11688_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/clind\/16.5.671","volume":"16","author":"J Montejo","year":"1993","unstructured":"Montejo J, Alberola I, Glez-Zarate P, Alvarez A, Alonso J, Canovas A, Aguirre C. Open, randomized therapeutic trial of six antimicrobial regimens in the treatment of human brucellosis. Clin Infect Dis. 1993;16(5):671\u20136.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"11688_CR38","first-page":"152","volume":"11","author":"M Ranjbar","year":"2007","unstructured":"Ranjbar M, Keramat F, Mamani M, Kia AR, Hashemi SH, Nojomi M. Comparison between doxycycline\u2013rifampin\u2013amikacin and doxycycline\u2013rifampin regimens in the treatment of brucellosis. IJID One Health. 2007;11(2):152\u20136.","journal-title":"IJID One Health"},{"issue":"3738","key":"11688_CR39","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4414\/smw.2004.10665","volume":"134","author":"MH Roushan","year":"2004","unstructured":"Roushan MH, Gangi SME, Ahmadi SAA. Comparison of the efficacy of two months of treatment with co-trimoxazole plus Doxycycline vs. co-trimoxazole plus Rifampin in brucellosis. Swiss Med Wkly. 2004;134(3738):564\u2013564.","journal-title":"Swiss Med Wkly"},{"issue":"8","key":"11688_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1086\/501359","volume":"42","author":"MRH Roushan","year":"2006","unstructured":"Roushan MRH, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus Doxycycline versus streptomycin plus Doxycycline in the treatment of brucellosis in humans. Clin Infect Dis. 2006;42(8):1075\u201380.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"11688_CR41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1093\/jac\/dkq064","volume":"65","author":"MH Roushan","year":"2010","unstructured":"Roushan MH, Amiri MS, Janmohammadi N, Hadad MS, Javanian M, Baiani M, Bijani A. Comparison of the efficacy of gentamicin for 5 days plus Doxycycline for 8 weeks versus streptomycin for 2 weeks plus Doxycycline for 45 days in the treatment of human brucellosis: a randomized clinical trial. J Antimicrob Chemother. 2010;65(5):1028\u201335.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"11688_CR42","first-page":"921","volume":"23","author":"N Saltoglu","year":"2002","unstructured":"Saltoglu N, Tasova Y, Inal AS, Seki T, Aksu HS. Efficacy of rifampicin plus Doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J. 2002;23(8):921\u20134.","journal-title":"Saudi Med J"},{"issue":"3","key":"11688_CR43","first-page":"318","volume":"17","author":"H Sarmadian","year":"2014","unstructured":"Sarmadian H, Didgar F, Ghasemikah R. Comparison between efficacy of Ciprofioxacin-Doxycycline with Rifampin\u2013Doxycycline regimens inrelapse of brucellosis. ISMJ. 2014;17(3):318\u201325.","journal-title":"ISMJ"},{"issue":"1","key":"11688_CR44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0163-4453(90)92214-6","volume":"20","author":"A Shehabi","year":"1990","unstructured":"Shehabi A, Shakir K, El-Khateeb M, Qubain H, Fararjeh N, Shamat ARA. Diagnosis and treatment of 106 cases of human brucellosis. J Infect. 1990;20(1):5\u201310.","journal-title":"J Infect"},{"issue":"9","key":"11688_CR45","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1128\/AAC.39.9.2061","volume":"39","author":"J Solera","year":"1995","unstructured":"Solera J, Rodriguez-Zapata M, Geijo P, Largo J, Paulino J, S\u00e1ez L, Martinez-Alfaro E, Sanchez L, Sepulveda M-A, Ruiz-Ribo M-D. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI group. Grupo de estudio de Castilla-la Mancha de enfermedades infecciosas. Antimicrob Agents Chemother. 1995;39(9):2061\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"11688_CR46","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4103\/AZMJ.AZMJ_61_22","volume":"20","author":"WA Hassan","year":"2022","unstructured":"Hassan WA, Abdel-Gawad M, Abdelmohsen AS. Doxycycline plus Trimethoprim-Sulfamethoxazole versus Doxycycline plus rifampicin in treatment of brucellosis: A randomized controlled trial. Al-Azhar Assiut Med J. 2022;20(4):333\u20137.","journal-title":"Al-Azhar Assiut Med J"},{"issue":"11","key":"11688_CR47","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"2","key":"11688_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijantimicag.2005.06.001","volume":"26","author":"G Pappas","year":"2005","unstructured":"Pappas G, Solera J, Akritidis N, Tsianos E. New approaches to the antibiotic treatment of brucellosis. Int J Antimicrob Agents. 2005;26(2):101\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"11688_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1128\/AAC.41.1.80","volume":"41","author":"J Solera","year":"1997","unstructured":"Solera J, Espinosa A, Martinez-Alfaro E, Sanchez L, Geijo P, Navarro E, Escribano J, Fern\u00e1ndez JA. Treatment of human brucellosis with Doxycycline and gentamicin. Antimicrob Agents Chemother. 1997;41(1):80\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"11688_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archinte.159.2.167","volume":"159","author":"D Raoult","year":"1999","unstructured":"Raoult D, Houpikian P, Dupont HT, Riss JM, Arditi-Djiane J, Brouqui P. Treatment of Q fever endocarditis: comparison of 2 regimens containing Doxycycline and Ofloxacin or hydroxychloroquine. Arch Intern Med. 1999;159(2):167\u201373.","journal-title":"Arch Intern Med"},{"issue":"3","key":"11688_CR51","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3947\/ic.2014.46.3.182","volume":"46","author":"D Son","year":"2014","unstructured":"Son D, Chung M-H. In vitro synergism between chloroquine and antibiotics against Orientia Tsutsugamushi. Infect Chemother. 2014;46(3):182\u20138.","journal-title":"Infect Chemother"},{"key":"11688_CR52","doi-asserted-by":"crossref","unstructured":"Pappas G, Christou L, Akritidis N, Tsianos E. Quinolones for brucellosis: treating old diseases with new drugs. In: Elsevier. 2006;12: 823\u2013825.","DOI":"10.1111\/j.1469-0691.2006.01442.x"},{"key":"11688_CR53","volume-title":"NCfEaZID: BRUCELLOSIS REFERENCE GUIDE: EXPOSURES","author":"(NCEZID)","year":"2017","unstructured":"(NCEZID). NCfEaZID: Brucellosis reference guide: exposures. testing, and prevention: CDC; 2017."},{"issue":"5","key":"11688_CR54","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/antibiotics12050860","volume":"12","author":"M Thy","year":"2023","unstructured":"Thy M, Timsit J-F, de Montmollin E. Aminoglycosides for the treatment of severe infection due to resistant gram-negative pathogens. Antibiotics. 2023;12(5):860.","journal-title":"Antibiotics"},{"key":"11688_CR55","doi-asserted-by":"crossref","unstructured":"Yousefi-Nooraie R, Mortaz\u2010Hejri S, Mehrani M, Sadeghipour P. Antibiotics for treating human brucellosis. Cochrane Database Syst Rev. 2012(10).","DOI":"10.1002\/14651858.CD007179.pub2"},{"issue":"1","key":"11688_CR56","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1586\/14787210.6.1.109","volume":"6","author":"JA Al-Tawfiq","year":"2008","unstructured":"Al-Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther. 2008;6(1):109\u201320.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"11688_CR57","unstructured":"Organization WH. WHO recommended strategies for the prevention and control of communicable diseases. In: WHO recommended strategies for the prevention and control of communicable diseases. edn. 2001."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11688-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:04:26Z","timestamp":1760490266000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11688-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11688"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11688-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors provided written informed consent to publish. All images in this article have been approved by me and I have signed an informed consent form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1308"}}